Genmab(DE:GE91)
€49.600.00 (0.00%)
DE:GE91
Genmab stock forecast
€49.60
At close:0.00 (0.00%)
Genmab (GE91) Stock Forecast & Price Target
3 Followers
GE91 Analyst Ratings
Strong Buy
8Buy1Hold0Sell
Based on 9 analysts giving stock ratings to Genmab in the past 3 months
GE91 Stock 12 Month Forecast
Average Price Target
€58.04▲(17.01% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Genmab in the last 3 months. The average price target is EUR 58.04 with a high forecast of EUR 71.74 and a low forecast of EUR 46.63. The average price target represents a 17.01% change from the last price of EUR 49.60.
Past 12 Months12 Month ForecastJan2026Oct2026
High€71.74
Average€58.04
Low€46.63
Highest Price TargetHighest€71.74Average Price Target€58.04Lowest Price TargetLowest€46.63
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Gregory Renza | Truist Financial | €60.09 | buy | 21.14%Upside | Reiterated | 11/06/26 | ||
| Sean Laaman | Morgan Stanley | €51.12 | hold | 3.06%Upside | Reiterated | 11/06/26 | ||
| Ram Selvaraju | H.C. Wainwright | €62.78 | buy | 26.57%Upside | Reiterated | 11/06/26 | ||
| Charlie Haywood | Bank of America Securities | ― | buy | ― | Reiterated | 11/06/26 | ||
| Asthika Goonewardene | Leerink Partners | €53.81→€58.29 | buy | 17.52%Upside | Reiterated | 10/29/26 | ||
| Rajan Sharma | Goldman Sachs | €30.04→€55.60 | buy | 12.10%Upside | Reiterated | 10/29/26 | ||
| Michael Schmidt | Guggenheim | €52.01→€71.74 | buy | 44.65%Upside | Reiterated | 10/29/26 | ||
| Matt Phipps | William Blair | ― | buy | ― | Reiterated | 10/29/26 | ||
| Yaron Werber | TD Cowen | €38.56→€46.63 | buy | -5.98%Downside | Assigned | 10/26/26 | ||
| Benjamin Jackson CFA | Jefferies | ― | buy | ― | Reiterated | 08/07/26 | ||
| James Gordon CFA | Barclays | ― | buy | ― | Reiterated | 08/07/26 | ||
| Eva Fortea Verdejo | Wells Fargo | €35.87 | buy | -27.68%Downside | Assigned | 06/29/26 | ||
| Kalpit Patel | Wolfe Research | €28.70 | buy | -42.14%Downside | Reiterated | 06/14/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Gregory RenzaTruist Financial | BuyReiterated€60.09 | 11/06/26 | 21.14%Upside | ||
| Sean LaamanMorgan Stanley | HoldReiterated€51.12 | 11/06/26 | 3.06%Upside | ||
| Ram SelvarajuH.C. Wainwright | BuyReiterated€62.78 | 11/06/26 | 26.57%Upside | ||
| Charlie HaywoodBank of America Securities | BuyReiterated | 11/06/26 | ― | ||
| Asthika GoonewardeneLeerink Partners | BuyReiterated€53.81→€58.29 | 10/29/26 | 17.52%Upside | ||
| Rajan SharmaGoldman Sachs | BuyReiterated€30.04→€55.60 | 10/29/26 | 12.10%Upside | ||
| Michael SchmidtGuggenheim | BuyReiterated€52.01→€71.74 | 10/29/26 | 44.65%Upside | ||
| Matt PhippsWilliam Blair | BuyReiterated | 10/29/26 | ― | ||
| Yaron WerberTD Cowen | BuyAssigned€38.56→€46.63 | 10/26/26 | -5.98%Downside | ||
| Benjamin Jackson CFAJefferies | BuyReiterated | 08/07/26 | ― | ||
| James Gordon CFABarclays | BuyReiterated | 08/07/26 | ― | ||
| Eva Fortea VerdejoWells Fargo | BuyAssigned€35.87 | 06/29/26 | -27.68%Downside | ||
| Kalpit PatelWolfe Research | BuyReiterated€28.70 | 06/14/26 | -42.14%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Genmab
3 Months
Success Rate13/16 ratings generated profit
81%
Average Return
+15.82%
Copying Matt Phipps's trades and holding each position for 3 Months would result in 81.25% of your transactions generating a profit, with an average return of +15.82% per trade.
1 Year
Success Rate10/10 ratings generated profit
100%
Average Return
+65.75%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +65.75% per trade.
2 Years
Success Rate16/16 ratings generated profit
100%
Average Return
+97.83%
Copying Matt Phipps's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +97.83% per trade.
GE91 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 2 | 1 |
| Buy | 17 | 21 | 15 | 28 | 23 |
| Hold | 4 | 4 | 4 | 4 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 24 | 28 | 20 | 34 | 27 |
In the current month, GE91 has received 24 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. GE91 average Analyst price target in the past 3 months is 58.04.
GE91 Financial Forecast
High€0.34
Consensus€0.20
Low€0.06
GE91 Earnings Forecast
Next quarter’s earnings estimate for GE91 is EUR 0.20 with a range of EUR 0.06 to EUR 0.34. The previous quarter’s EPS was EUR 0.50. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€1.17B
Consensus€1.13B
Low€1.09B
GE91 Sales Forecast
Next quarter’s sales forecast for GE91 is EUR 1.13B with a range of EUR 1.09B to EUR 1.17B. The previous quarter’s sales results were EUR 1.07B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
GE91 Stock Forecast FAQ
What is DE:GE91’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab’s 12-month average price target is €58.04.
What is DE:GE91’s upside potential, based on the analysts’ average price target?
Genmab has 17.01% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Genmab a Buy, Sell or Hold?
Genmab has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Genmab’s share price target?
The average share price target for Genmab is €58.04. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €71.74, and the lowest forecast is €46.63. The average share price target represents a 17.01% increase from the current price of €49.6.
What do analysts say about Genmab?
Genmab’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of Genmab?
To buy shares of DE:GE91, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
